fda warning letters compounded semaglutide tirzepatide september 2025 Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP-1 compounding while @martymakary is photographed holding bootleg # FDA Warns 30 Telehealth Companies

Expanding the labeled indication to include OSA opened the door to payer-supported access to GLP-1 therapy for patients with obesity-associated OSA, with the potential to reduce reliance on devices

Individual experiences may vary, and consistent use is important for optimal results

Frequently asked questions (FAQs) about orforglipron Here are answers to some of the most common questions about orforglipron

Seek urgent medical care if you experience blood glucose levels persistently above 300 mg/dL, symptoms of severe hyperglycemia, dehydration, or signs of diabetic ketoacidosis

Of the 32 participants who received tirzepatide, ten participants reported a total of 25 treatment-emergent adverse events

Their idea was backed up by the findings of Unger and other researchers like Keith Buchanan, a Scottish specialist in metabolic medicine at Queens University in Belfast, Northern Ireland (Marks 2018